Intrahepatic cholangiocarcinoma

2 papers

Animals1
In silico1

Trial sponsors

TransThera Sciences
Company1 trialPhase 3138 people
Delcath Systems
Company1 trialPhase 2/3295 people
Sirtex Medical
Company1 trialPhase 2/389 people
Lisata Therapeutics
Company1 trialPhase 266 people
CSPC Ouyi Pharmaceutical
Company1 trialPhase 217 people
Zhiyong Huang
1 trialPhase 420 people
Shi Ming
2 trialsPhase 3376 people
Zhejiang Cancer Hospital
2 trialsPhase 3160 people

Latest

1 in 12 months

Translational OncologyApr 4

EGR1 lactylation induces tumor cell senescence and immunosuppressive microenvironment in intrahepatic cholangiocarcinoma

Experiments in animalsCellular senescence

Journal of CancerApr 5

Machine Learning-based Development and Validation of a Cell Senescence Predictive and Prognostic Signature in Intrahepatic Cholangiocarcinoma

Computational studyBiomarkers

Journal of HepatologyAug 22

Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling

Experiments in animalsInterventions

AgingOct 12

Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics

ReviewMechanisms